Pletaal/Pletaal SR

Pletaal/Pletaal SR



Otsuka (Philippines)


Otsuka (Philippines)
Full Prescribing Info
Relief of various ischemic symptoms such as ulcer, pain and cold sensation due to chronic arterial occlusive diseases. Prevention of recurrence of cerebral infarction excluding cardiogenic cerebral embolism.
Pletaal: Management of peripheral vascular disease.
Dosage/Direction for Use
Pletaal: Adult 100 mg twice daily.
Pletaal SR: Adult 200 mg once daily.
Congestive heart failure. Hemophilia, increased capillary fragility, hemoptysis; intracranial, digestive and urinary tract and vitreous body hemorrhage. Women of childbearing potential. Pregnancy.
Special Precautions
Monitor for any anginal symptoms such as chest pain. Asymptomatic cerebral infarction. Concomitant use with anticoagulants, antiplatelet and thrombolytic drugs or prostaglandin E1 or its derivatives. Risk of hemorrhagia during menstruation; bleeding tendency or predisposition; severe hepatic or renal impairment; coronary artery stenosis; diabetes mellitus or abnormal glucose tolerance; malignant hypertension. Discontinue use or reduce dose if excessive increase in pulse rate is observed in patients with coronary artery stenosis. Long-term use in patients without congestive heart failure. Lactation. Children. Elderly.
Adverse Reactions
Rash; palpitation, tachycardia, hot flushes; headache/dull headache, dizziness, insomnia, numbness; abdominal pain, nausea, vomiting, anorexia, diarrhea, heartburn and abdominal distention; subcutaneous hemorrhage; increased ALT, AST, alkaline phosphatase and lactate dehydrogenase; sweating, edema and chest pain.
Drug Interactions
Anticoagulants such as warfarin, antiplatelets such as aspirin and ticlopidine hydrochloride, thrombolytics such as urokinase and alteplase, prostaglandin E1 or its derivatives such as alprostadil, limaprost, alfadex; CYP3A4 inhibitors including macrolides such as erythromycin, HIV protease inhibitors such as ritonavir, azole antimycotics such as itraconazole and miconazole, cimetidine, diltiazem hydrochloride and grapefruit juice; CYP2C19 inhibitors such as omeprazole.
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AC23 - cilostazol ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Pletaal: Tab 50 mg x 100's. 100 mg x 100's. Powd for oral liqd (sachet) 50 mg x 140's. 100 mg x 140's.
Pletaal SR: SR cap 100 mg x 30's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in